CDKN2B and central nervous system cancer: CDKN2B-AS1, also referred to as ANRIL, is a long non-coding RNA (lncRNA) that downregulates CDKN2B expression when transcribed, through cis-acting heterochromatin formation.18,19ANRIL has been previously reported as a major GWAS hotspot,20 with multiple associations reported for cardiovascular phenotypes21,22 and neoplasms,23 including glioma.24CDKN2A encodes p16(INK4a) and p14(ARF); these gene products are translated from different reading frames of the CDKN2A gene and are therefore distinct proteins and not isoforms of one another.